Advertisement

Macrovascular Disease

  • Ronald A. Codario
Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

Type-2 diabetes, by virtue of its predisposition to generalized arteriosclerotic vascular disease, inflammatory milieu, and thrombogenesis is truly a vasculopathic state.

Key Words

Coronary artery disease Peripheral vascular disease Cerebral arteriosclerotic vascular disease Generalized arteriosclerotic vascular disease Hyperinsulinemia 

References

  1. 1.
    Deckert T, et al. Implications for micro-and macrovascular disease. Diabetes Care 1992;15:1181–1191.PubMedCrossRefGoogle Scholar
  2. 2.
    Greenfield S, Billimek J, Pellegrini F, Franciosi M, DeBerardis G. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. Ann Intern Med 2009;151:854–860.PubMedCrossRefGoogle Scholar
  3. 3.
    Haffner SM, Lehto S, et al. Mortality from coronary artery disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234.PubMedCrossRefGoogle Scholar
  4. 4.
    Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type-2 diabetes. Ann Intern Med 2009;151:394–403.PubMedCrossRefGoogle Scholar
  5. 5.
    Stamler J, Caccaro O, Neaton JD, Wentrworth D. Diavetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care 1993;16:434–444.PubMedCrossRefGoogle Scholar
  6. 6.
    Gilpin E, Ricou F, et al. Factors associated with recurrent myocardial infarction within one year after acute myocardial infarction. Am Heart J 1991;121:457–463.PubMedCrossRefGoogle Scholar
  7. 7.
    Herlitz J, Malmberg K, et al. Mortality and morbidity during a five year follow up of diabetics with myocardial infarction. Acta Med Scand 1988;224:31–38.PubMedCrossRefGoogle Scholar
  8. 8.
    Eschwege E, Richard JL, Thibult N. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study. Horn Metab Res Suppl 1985;15:41–46.Google Scholar
  9. 9.
    Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755–1762.PubMedCrossRefGoogle Scholar
  10. 10.
    Lehto, S, Pyorala K, Miettinen H, et al. Myocardial infarct size and mortality in patients with non-insulin dependent diabetes mellitus. J Intern Med 1994;236:291–297.PubMedCrossRefGoogle Scholar
  11. 11.
    Uusitupa M, et al. The relationship of cardiovascular risk factors to the prevalence of coronary heart disease in newly diagnosed type 2 diabetes. Diabetolologia 1985;28:653–659.CrossRefGoogle Scholar
  12. 12.
    Fuller JH, et al. Coronary heart disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980;1:1373–1376.PubMedCrossRefGoogle Scholar
  13. 13.
    Jarrett RJ, et al. Diabetes mellitus and cardiovascular disease – putative association via common antecedents. Diabetologia 1988;31:737–740.PubMedCrossRefGoogle Scholar
  14. 14.
    Levine GN, Jacobs AK, et al. Impact of diabetes mellitus on percutaneous revascularization CAVEAT-I Investigators. Coronary Angioplasty versus Excisional Atherectomy Trial. Am J Cardiol 1997;79:748–755.PubMedCrossRefGoogle Scholar
  15. 15.
    Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Vasc Med 1998;3(3):257–260.PubMedGoogle Scholar
  16. 16.
    Van Belle E, Bauters C, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997;96:1454–1460.PubMedCrossRefGoogle Scholar
  17. 17.
    Taylor GJ, Moses HW, et al. Six year survival after coronary thrombolysis and early revascularization for acute myocardial infarction. Am J Cardiol 1992;70:26–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Elliot WJ, Meyer PM. Incident diabetesin clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369(9557):201–207.CrossRefGoogle Scholar
  19. 19.
    Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation 1997;96:4239–4245.PubMedCrossRefGoogle Scholar
  20. 20.
    Patti G, Nusca A, DiSciascio G. Meta-analysis comparison (Nine Trilas) of outcomes with drug eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2008;102:1328–1334.PubMedCrossRefGoogle Scholar
  21. 21.
    FRISC II Investigators. Long term low molecular mass heparin in unstable angina: FRISC-II multicenter study. Lancet 1999;354:701–707.Google Scholar
  22. 22.
    Ridker P, Cushman M, Stampfer M, Tracy R. Inflammation, aspirin and risk of cardiovascular disease in healthy men. N Engl J Med 1997;337(5):356.Google Scholar
  23. 23.
    Hiatt WR. New treatment options in intermittent claudication. In J Clin Pract Suppl 2001;119:20–27.Google Scholar
  24. 24.
    Criqui MH, Langer RD, Fronek A. Mortality over a period of 10 years in patients with peripheral vascular disease. N Engl J Med 1992;326:381–386.PubMedCrossRefGoogle Scholar
  25. 25.
    Jensen-Urstad KJ, Reichard PG, et al. Early atherosclerosis is retarded by improved long term blood glucose control in patients with IDDM. Diabetes 1996;45:1253–1258.PubMedCrossRefGoogle Scholar
  26. 26.
    Donnelly R. Assessment and management of intermittent claudication: importance of secondary prevention. Int J Clin Pract Suppl 2001;119:2–9.PubMedGoogle Scholar
  27. 27.
    McDermott MM, Guralnik JM, Greenland P. Statin use and leg functioning in patients with and without lower extremity peripheral arterial disease. Circulation 2003;107:757–761.PubMedCrossRefGoogle Scholar
  28. 28.
    Hiatt WR. New treatment options in intermittent claudication: the US experience. Int J Clin Pract Suppl 2001:119:20–37.PubMedGoogle Scholar
  29. 29.
    North American Symptomatic Carotid Endarterecdtomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med 1991;325:445–453.CrossRefGoogle Scholar
  30. 30.
    Rothwell PM, Gutnikoff SA, Warlow CP. Reanalysis of the European Carotid Surgery Trial. Stroke 2003;34:514.PubMedCrossRefGoogle Scholar
  31. 31.
    Sauve JS, Thorpe KE, Sackett DL. The North American Symptomatic Carotid Endarterectomy Trial. Can bruits distinguish high grade from moderate symptomatic carotid Stenosis? Ann Intern Med 1994;120:633–637.PubMedCrossRefGoogle Scholar
  32. 32.
    Vijan S, Hayward RA. Pharmacologic lipid lowering therapy in type-2 diabetes mellitus. Ann Intern Med 2004;140:650–658.PubMedCrossRefGoogle Scholar
  33. 33.
    Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox. Circulation 2002;106:2760–2763.PubMedCrossRefGoogle Scholar
  34. 34.
    Dahlof B, Kjeldsen RB, Julius SE, Beevers S, de Faire U. Cardiovascular mortality and morbidity in the losartan intervention for endpoint reduction in hypertension study (LIFE). Lancet 2002;359(9311):995–1003.PubMedCrossRefGoogle Scholar
  35. 35.
    Vinik A, Vinik E. Prevention of the complications of diabetes. Am J Manag Care 2003;9(3):S63–S77.Google Scholar

Supplementary Readings

  1. Agewall S, Fagerberg B, et al. Carotid artery wall intima media thickness is associated with insulin mediated glucose disposal in men at high and low coronary risk. Stroke 1995;26:956–960.PubMedCrossRefGoogle Scholar
  2. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 1998;21:1551–1559.CrossRefGoogle Scholar
  3. Aronson D, Bloomgarden Z, et al. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528–535.PubMedCrossRefGoogle Scholar
  4. Brownlee M, et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–1321.PubMedCrossRefGoogle Scholar
  5. Carrozza J, Kuntz R, et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344–349.PubMedCrossRefGoogle Scholar
  6. Clark RS, English M, et al. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. BMJ 1985;291:303–305.PubMedCrossRefGoogle Scholar
  7. Fava S, Azzopardi J, et al. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 1993;16:1615–1618.PubMedCrossRefGoogle Scholar
  8. Gum P, O’Keefe JJ, et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 1997;96(9 Suppl):II7–II10.Google Scholar
  9. Kornowski R, Mintz GS, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation 1997;95:1366–1369.PubMedCrossRefGoogle Scholar
  10. Krolewski AS, et al. Magnitude and determinants of coronary artery disease in juvenile onset, insulin dependent diabetes mellitus. Am J Cardiol 1987;59:750–755.PubMedCrossRefGoogle Scholar
  11. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B–31B.PubMedCrossRefGoogle Scholar
  12. Sobel BE. Acceleration of restenosis by diabetes. Circulation 2001;103:1185–1187.PubMedCrossRefGoogle Scholar
  13. Soler NG, Bennett MA, et al. Myocardial infarction in diabetics. Q J Med 1975;44:125–132.PubMedGoogle Scholar
  14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977–996.CrossRefGoogle Scholar
  15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837–853.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ronald A. Codario
    • 1
  1. 1.University of Pennsylvania Health System Thomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations